Related Experiment Videos
Molecular cancer therapeutics: recent progress and targets in drug resistance
1Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032.
Abstract:
Recent progress in development of molecular cancer therapeutics revealed new types of antitumor drugs, such as Herceptin, Gleevec, and Iressa as potent therapeutics for each specific tumor. We have been working on molecular cancer therapeutics, and in particular, those related to drug resistance, Here, I describe several resistance mechanisms, including apoptosis regulation, cellular stress response and cellular survival signals which have show close relevance to drug resistance. P-glycoprotein (P-gp) is the key molecule in multidrug resistance (MDR) and a good target for chemotherapy. Proteasome is involved in the resistance mechanism to topo II-targeted chemotherapy in solid tumors. Apoptosis program in tumor cells plays a critical role in chemotherapy-induced tumor cell killing, and the blockade of the apoptosis-inducing pathway could be another mechanism for drug resistance. Glyoxalase I is a molecule involved in apoptosis resistance mechanism in tumors. Survival (antiapoptosis) signals are the good targets for various antitumor drugs to overcome innate drug resistance. Our present studies provide novel targets for effective molecular cancer therapeutics in future.
Insights
Understanding cancer drug resistance mechanisms, like P-glycoprotein (P-gp) and apoptosis regulation, is key to developing effective molecular cancer therapeutics. Targeting these pathways offers new strategies against tumor resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Molecular cancer therapeutics have advanced, with drugs like Herceptin, Gleevec, and Iressa showing tumor-specific efficacy.
- Drug resistance remains a significant challenge in cancer treatment, necessitating research into underlying mechanisms.
- Understanding resistance is crucial for developing next-generation molecular cancer therapeutics.
Purpose of the Study:
- To elucidate key molecular mechanisms of cancer drug resistance.
- To identify novel molecular targets for overcoming therapeutic resistance in tumors.
- To explore the role of apoptosis regulation, cellular stress, and survival signals in drug resistance.
Main Methods:
- Review and synthesis of current research on cancer drug resistance mechanisms.
- Analysis of the role of specific molecules like P-glycoprotein and Glyoxalase I in resistance.
- Examination of cellular processes such as apoptosis and stress response in relation to drug efficacy.
Main Results:
- Multidrug resistance (MDR) is often mediated by molecules like P-glycoprotein (P-gp).
- Proteasome activity and the apoptosis pathway blockade are implicated in resistance to chemotherapy.
- Glyoxalase I and anti-apoptosis survival signals contribute to tumor resistance and represent potential therapeutic targets.
Conclusions:
- Several molecular mechanisms, including P-gp, proteasome activity, apoptosis regulation, and survival signals, are critical in cancer drug resistance.
- Targeting these resistance mechanisms, such as Glyoxalase I and survival pathways, offers promising strategies for future molecular cancer therapeutics.
- Further research into these targets can lead to more effective treatments for drug-resistant tumors.